Nearly 250 dead, a thousand suspected cases, and no approved vaccine exists.
In the forests and conflict zones straddling the Democratic Republic of Congo and Uganda, a rare and largely unfamiliar strain of Ebola — the Bundibugyo species — has claimed nearly 250 lives and touched more than a thousand, exposing once again how swiftly nature can outpace human preparation. Three research teams, armed with different technologies and a shared urgency, are now compressing years of scientific work into months, racing to produce a vaccine for a virus that has never before demanded one at this scale. The effort is a testament to both how far medicine has come since the catastrophic West African epidemic of 2014 and how much remains unfinished in the long human project of epidemic readiness.
- A rare Ebola species with no approved vaccine has killed nearly 250 people and infected over 1,000 across DR Congo and Uganda, with officials warning it could rival the deadliest Ebola outbreak in history.
- The virus first spread undetected through a conflict zone with almost no healthcare infrastructure, giving it precious weeks of unchecked momentum before the world took notice.
- Nine confirmed cases have already crossed into Uganda, signaling that borders offer little protection when a pathogen moves faster than the systems designed to stop it.
- IAVI, Moderna, and Oxford are each compressing normal development timelines — from years to months — using three distinct technologies, all targeting the same vulnerable structure on the virus's surface.
- The critical unknowns — how well each vaccine works, how many doses are needed, how fast immunity builds — cannot be answered until human trials begin, and trials have not yet begun.
Nearly 250 people are dead and more than a thousand suspected cases have emerged across the Democratic Republic of Congo and into Uganda. The culprit is Bundibugyo Ebola — a rare species that has appeared in human populations only twice before and for which no approved vaccine exists. Three separate research teams are now racing to change that.
The International Aids Vaccine Initiative, Moderna, and the University of Oxford have each launched vaccine programs, all funded by the Coalition for Epidemic Preparedness Innovations. IAVI has warned that this outbreak could rival or surpass the West African epidemic of 2014 to 2016, when nearly 29,000 people were infected and more than 11,000 died. Médecins Sans Frontières has described the pace of new cases as unprecedented.
The core scientific challenge is that Ebola's six distinct species do not share immunity — a vaccine for one offers no protection against another. IAVI is adapting its existing Zaire Ebola vaccine to target Bundibugyo instead, with monkey trials showing near-complete protection. It estimates seven to nine months before human clinical trials. Moderna, drawing on its mRNA experience from the Covid pandemic, believes it can have a candidate ready in two to three months. Oxford is pursuing a similar genetic delivery approach. All three vaccines aim at the same target: a structure on the virus's surface called the Bundibugyo glycoprotein.
The differences in technology matter in ways that only trials can resolve — affecting protection levels, dosage requirements, and the speed at which immunity develops. Meanwhile, the outbreak was already spreading through a conflict zone with minimal healthcare infrastructure before it was even detected. Nine confirmed cases have now crossed into Uganda.
The Coalition for Epidemic Preparedness Innovations is funding all three efforts, and its leadership has been clear: time is the scarcest resource. Whether any of these vaccines will arrive before the outbreak reaches catastrophic scale remains an open and urgent question.
Nearly 250 people are dead. More than a thousand suspected cases have emerged across the Democratic Republic of Congo and into Uganda. The virus is Bundibugyo Ebola—a rare species that has only surfaced twice before in human populations, and for which no approved vaccine exists. Now three separate research teams are racing to develop one.
The International Aids Vaccine Initiative, the pharmaceutical company Moderna, and the University of Oxford have each launched vaccine programs, all funded by the Coalition for Epidemic Preparedness Innovations. The urgency is not abstract. Officials at IAVI have warned that this outbreak threatens to become as severe as, or worse than, the West African epidemic of 2014 to 2016, when nearly 29,000 people were infected and more than 11,000 died. Médecins Sans Frontières has called the situation deeply alarming, noting that never before have so many cases appeared so quickly.
The challenge is that Ebola comes in six distinct species, and a vaccine for one does not protect against another. There is an approved vaccine for Zaire Ebola, the most common form, but Bundibugyo is different. IAVI is taking its existing Zaire vaccine and modifying it to target Bundibugyo instead. In monkey trials, the experimental version rapidly trained the immune system and provided close to complete protection. The organization estimates it will need seven to nine months to prepare the vaccine for human clinical trials, though researchers are pushing to compress that timeline.
Moderna is pursuing a different path, deploying the mRNA technology that proved its worth during the Covid pandemic. The company says it can have a candidate ready for clinical trials in two to three months. The University of Oxford is also working with genetic code delivery, similar to Moderna's approach. All three vaccines aim to teach the body's immune system to recognize the same target on the virus's surface—a structure called the Bundibugyo glycoprotein. When the real virus arrives, the immune system will already know what to attack.
But the technologies differ in how they accomplish this. IAVI's approach uses a harmless engineered virus that carries the Ebola glycoprotein; the body fights off the harmless virus and learns to recognize Ebola in the process. Moderna and Oxford both deliver a snippet of genetic instructions that tell the body to manufacture the glycoprotein itself, triggering an immune response. These differences matter. They could affect how well each vaccine protects, how many doses a person needs, and how quickly immunity develops. None of that can be known until clinical trials begin.
The outbreak was first detected only after it had already spread through a conflict zone with minimal healthcare infrastructure—a detail that compounds the danger. With no vaccine available and limited medical resources in the affected region, the virus has had room to move. Nine confirmed cases have now reached Uganda, across the border from the epicenter in DR Congo. Officials at the World Health Organization have emphasized that a working vaccine could not only help contain this epidemic but also strengthen preparedness for future outbreaks of the same virus.
For now, the race is measured in months. Moderna's two to three month timeline is the shortest; IAVI's seven to nine months is longer but still represents an acceleration of normal development schedules. The Coalition for Epidemic Preparedness Innovations is funding all three efforts, and its leadership has made clear that time is the scarcest resource. Every day the virus spreads unchecked is a day it gains ground. The vaccines are coming, but whether they will arrive in time to prevent this outbreak from reaching the scale of the West African catastrophe remains an open question.
Notable Quotes
This is clearly threatening to be as severe an outbreak as that, if not even worse, and development of a vaccine is clearly a priority.— Dr. Mark Feinberg, head of IAVI
With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease.— Dr. Richard Hatchett, CEO of CEPI
The Hearth Conversation Another angle on the story
Why does Bundibugyo matter more than the other Ebola species? It seems like there should already be tools for this.
Because it's rare. We have a vaccine for Zaire Ebola, which is the one we know best. But Bundibugyo has only shown up twice before in human populations. No one invested in a vaccine for something that seemed like a ghost.
So when it appeared this time, there was nothing ready.
Exactly. And it appeared in a conflict zone where people couldn't easily get to hospitals or report cases early. By the time anyone noticed, it had already spread to over a thousand suspected cases.
The three vaccines use different technologies. Does that mean one will definitely work better?
Not necessarily. They're all targeting the same thing on the virus—the glycoprotein. But the way they train your immune system is different. One uses a harmless virus as a messenger. Two use genetic code. Which approach works best, and how many doses you need—that's what the trials will show.
Moderna says two to three months. That's fast.
It is. They've already built the infrastructure for mRNA vaccines during Covid. They know how to move quickly. But fast doesn't mean certain. The trials still have to happen, and they have to prove the vaccine actually protects people.
What happens if none of them work?
Then we're in serious trouble. This outbreak is already being compared to 2014 in West Africa, when eleven thousand people died. Without a vaccine, the only tools are isolation, contact tracing, and basic infection control—and those are hard to do in a conflict zone.